These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 31024569)

  • 1. Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.
    Amlani A; Choi MY; Tarnopolsky M; Brady L; Clarke AE; Garcia-De La Torre I; Mahler M; Schmeling H; Barber CE; Jung M; Fritzler MJ
    Front Immunol; 2019; 10():745. PubMed ID: 31024569
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis.
    Pluk H; van Hoeve BJ; van Dooren SH; Stammen-Vogelzangs J; van der Heijden A; Schelhaas HJ; Verbeek MM; Badrising UA; Arnardottir S; Gheorghe K; Lundberg IE; Boelens WC; van Engelen BG; Pruijn GJ
    Ann Neurol; 2013 Mar; 73(3):397-407. PubMed ID: 23460448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of anti-NT5C1A antibodies in Japanese patients with autoimmune rheumatic diseases in comparison with other patient cohorts.
    Muro Y; Nakanishi H; Katsuno M; Kono M; Akiyama M
    Clin Chim Acta; 2017 Sep; 472():1-4. PubMed ID: 28687351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sporadic Inclusion Body Myositis and Autoantibodies].
    Yamashita S; Ando Y
    Brain Nerve; 2018 Apr; 70(4):449-457. PubMed ID: 29632292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.
    Goyal NA; Cash TM; Alam U; Enam S; Tierney P; Araujo N; Mozaffar FH; Pestronk A; Mozaffar T
    J Neurol Neurosurg Psychiatry; 2016 Apr; 87(4):373-8. PubMed ID: 25857661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis.
    Kramp SL; Karayev D; Shen G; Metzger AL; Morris RI; Karayev E; Lam Y; Kazdan RM; Pruijn GJ; Saschenbrecker S; Dähnrich C; Schlumberger W
    Auto Immun Highlights; 2016 Dec; 7(1):16. PubMed ID: 27858337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
    Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
    Front Immunol; 2018; 9():1200. PubMed ID: 29922285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathomechanisms of anti-cytosolic 5'-nucleotidase 1A autoantibodies in sporadic inclusion body myositis.
    Tawara N; Yamashita S; Zhang X; Korogi M; Zhang Z; Doki T; Matsuo Y; Nakane S; Maeda Y; Sugie K; Suzuki N; Aoki M; Ando Y
    Ann Neurol; 2017 Apr; 81(4):512-525. PubMed ID: 28318044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases.
    Lloyd TE; Christopher-Stine L; Pinal-Fernandez I; Tiniakou E; Petri M; Baer A; Danoff SK; Pak K; Casciola-Rosen LA; Mammen AL
    Arthritis Care Res (Hoboken); 2016 Jan; 68(1):66-71. PubMed ID: 25892010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-cN1A antibodies do not correlate with specific clinical, electromyographic, or pathological findings in sporadic inclusion body myositis.
    Paul P; Liewluck T; Ernste FC; Mandrekar J; Milone M
    Muscle Nerve; 2021 Apr; 63(4):490-496. PubMed ID: 33373040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.
    Yeker RM; Pinal-Fernandez I; Kishi T; Pak K; Targoff IN; Miller FW; Rider LG; Mammen AL;
    Ann Rheum Dis; 2018 May; 77(5):714-719. PubMed ID: 29363513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Valosin-Containing Protein (VCP/p97) Autoantibodies in Inclusion Body Myositis and Other Inflammatory Myopathies.
    Amlani A; Choi MY; Buhler KA; Hudson M; Tarnopolsky M; Brady L; Schmeling H; Swain MG; Stingl C; Reed A; Fritzler MJ
    ACR Open Rheumatol; 2023 Jan; 5(1):10-14. PubMed ID: 36373433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.
    Herbert MK; Stammen-Vogelzangs J; Verbeek MM; Rietveld A; Lundberg IE; Chinoy H; Lamb JA; Cooper RG; Roberts M; Badrising UA; De Bleecker JL; Machado PM; Hanna MG; Plestilova L; Vencovsky J; van Engelen BG; Pruijn GJ
    Ann Rheum Dis; 2016 Apr; 75(4):696-701. PubMed ID: 25714931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of anti-cytosolic 5'-nucleotidase 1A antibody in idiopathic inflammatory myopathies.
    Ikenaga C; Findlay AR; Goyal NA; Robinson S; Cauchi J; Hussain Y; Wang LH; Kershen JC; Beson BA; Wallendorf M; Bucelli RC; Mozaffar T; Pestronk A; Weihl CC
    Ann Clin Transl Neurol; 2021 Mar; 8(3):571-578. PubMed ID: 33556224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myositis-related autoantibody profile and clinical characteristics stratified by anti-cytosolic 5'-nucleotidase 1A status in connective tissue diseases.
    Diederichsen LP; Iversen LV; Nielsen CT; Jacobsen S; Hermansen ML; Witting N; Cortes R; Korsholm SS; Krogager ME; Friis T
    Muscle Nerve; 2023 Jul; 68(1):73-80. PubMed ID: 37177880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.
    Lilleker JB; Rietveld A; Pye SR; Mariampillai K; Benveniste O; Peeters MT; Miller JA; Hanna MG; Machado PM; Parton MJ; Gheorghe KR; Badrising UA; Lundberg IE; Sacconi S; Herbert MK; McHugh NJ; Lecky BR; Brierley C; Hilton-Jones D; Lamb JA; Roberts ME; Cooper RG; Saris CG; Pruijn GJ; Chinoy H; van Engelen BG;
    Ann Rheum Dis; 2017 May; 76(5):862-868. PubMed ID: 28122761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility.
    Herbert MK; Pruijn GJ
    Curr Opin Rheumatol; 2015 Nov; 27(6):595-600. PubMed ID: 26285103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sporadic inclusion body myositis and primary Sjogren's syndrome: an overlooked diagnosis.
    Chung SH; Bent EI; Weiss MD; Gardner GC
    Clin Rheumatol; 2021 Oct; 40(10):4089-4094. PubMed ID: 33884496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: Report of 40 patients from a single neuromuscular center.
    Felice KJ; Whitaker CH; Wu Q; Larose DT; Shen G; Metzger AL; Barton RW
    Neuromuscul Disord; 2018 Aug; 28(8):660-664. PubMed ID: 30001928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic 5'-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility.
    Greenberg SA
    Muscle Nerve; 2014 Oct; 50(4):488-92. PubMed ID: 24752512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.